Endogenous inhibitors of nitric oxide synthesis in patients with bronchial asthma associated with arterial hypertension
https://doi.org/10.31549/2542-1174-2020-2-89-97
Abstract
288 patients were examined to study the level of endogenous inhibitors of nitric oxide in patients with bronchial asthma (BA) associated with arterial hypertension (AH): 96 patients — with BA, 96 patients — with AH and 96 patients — with BA + AH. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), N-monomethyl L-arginine (NMMA) and L-arginine determined by method of high-performance liquid chromatography, total nitric oxide — by photometric method. It is revealed that the comorbid course of bronchial asthma and arterial hypertension is characterized by a significant increase in serum concentration of ADMA, SDMA and NMMA having significant correlation with blood nitric oxide level. Decrease in concentration of endogenous inhibitors of nitric oxide in this cohort of patients can represent a perspective pharmacological task.
About the Authors
A. N. Stafeev
Novosibirsk State Medical University
Russian Federation
Russian Federation
Post-graduate Student, Department of Therapy, Hematology and Transfusiology,
52, Krasny Prospect, Novosibirsk, 630091
N. I. Logvinenko
Novosibirsk State Medical University
Russian Federation
Russian Federation
Dr. Sci. (Med.), Professor, Department of Therapy, Hematology and Transfusiology,
Novosibirsk
P. P. Tereshkov
Chita State Medical Academy
Russian Federation
Russian Federation
Cand. Sci. (Med.), Head Clinical Laboratory,
Chita
A. V. Melnik
City Clinical Hospital No. 25 (Novosibirsk)
Russian Federation
Russian Federation
Deputy Chief Doctor for Therapeutic Care,
Novosibirsk
S. V. Astrakov
City Clinical Hospital No. 25 (Novosibirsk)
Russian Federation
Russian Federation
Dr. Sci. (Med.), Chief Physician,
Novosibirsk
References
1. Global Strategy for Asthma Management and Prevention. Retrieved April 25, 2004 from http://www.ginasthma.com
2. Shahanov A.V. (2017). Clinical significance of polymorphism of NOS1 and NOS3 and nitric oxide genes in patients with bronchial asthma and hypertension: Cand. Sci. (Med.) Thesis. Ryazan, 2017. In Russ.
3. Shalnova S.A., Balanova Y.A., Konstantinov V.V. (2006). Arterial hypertension: prevalence, awareness, administration of antihypertensive drugs and effectiveness of treatment among the population of the Russian Federation. Russian Journal of Cardiology, 4 (60), 45–50. In Russ.
4. Vertkin A.L., Scotnikov A.S. (2013). Comorbidity. Attending Physician, 8, 78. In Russ.
5. Kuznik B.I. (2010). Cellular and Molecular Mechanisms of Regulation of Hemostasis in Norm and Pathology. Express Publishing House: Chita. In Russ.
6. Lyamina S.V., Rebrov A.P., Lyamina N.P., Senchichin V.N. (2007). Diagnostic significant markers of endothelial dysfunction in patients of young age with arterial hypertension. Regional Blood Circulation and Microcirculation, 6 (3), 59–65. In Russ.
7. Kumar R., Kohli S., Mishra A. et al. (2015). Interactions between the genes of vasodilatation pathways infl uence blood pressure and nitric oxide level in hypertension. Am. J. Hypertens., 28 (2), 239–247. doi: 10.1093/ajh/hpu130.
8. Belozerov V.K., Rubanova M.P., Weber V.R. et al. (2014). Endothelium-dependent vasodilation and carotid artery wall condition. Cardiovascular Therapy and Prevention, 13 (2), 16. In Russ.
9. Dzugkoyev S.G., Dzugkoyeva F.S., Margiyeva O.I., Mozhayeva I.V., Garmash O.Yu. (2019). The participation of biochemical systems in the pathogenesis of endothelial dysfunction. Modern Science and Education, 2, 143. In Russ.
10. Radaykina O.G., Vlasov A.P., Myshkina N.A. (2018). Role of endothelial dysfunction in the cardiovascular system pathology. Ulyanovsk Medical and Biological Journal, 4, 8–17.
11. Brinkmann S.J., de Boer M.C., Buijs N., van Leeuwen P.A. (2014). Asymmetric dimethylarginine and critical illness. Curr. Opin. Clin. Nutr. Metab. Care, 17, 90–97.
12. Leiper J., Vallance P. (1999). Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc. Res., 43, 542–548.
13. Tain Y.L., Hsu C.N. (2017). Toxic dimethylarginines: asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA). Toxins (Basel), 9 (3), pii: Е 92. doi: 10.3390/toxins9030092.
14. Rodionov R.N., Blokhin I.O., Galagudza M.M., Shlyakhto E.V., Lentz S.R. (2008). The emerging role of asymmetric dimethylarginine in cardiovascular diseases. Arterial Hypertension, 14 (4), 306–314.
15. Kielstein J.T., Salpeter S.R., Bode-Boeger S.M., Cooke J.P., Fliser D. (2006). Symmetric dimethylarginine (SDMA) as endogenous marker of renal function — A meta-analysis. Nephrol. Dial. Transplant., 21 (9), 2446–2451.
16. Schlesinger S., Sonntag S.R., Lieb W., Maas R. (2016). Asymmetric and symmetric dimethylarginine as risk markers for total mortality and cardiovascular outcomes: A systematic review and meta-analysis of prospective studies. PLoS ONE, 11 (11): е0165811. doi: 10.1371/journal.pone.0165811.
17. Jacobi J., Tsao P.S. (2008). Asymmetrical dimethylarginine in renal disease: Limits of variation or variation limits? A systematic review. Am. J. Nephrol., 28 (2), 224–237.
18. Zoccali C., Bode-Böger S., Mallamaci F. et al. (2001). Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet, 358 (9299), 2113–2117.
19. Bode-Böger S.M., Scalera F., Ignarro L.J. (2007). The L-arginine paradox: Importance of the L-arginine/ asymmetrical dimethylarginine ratio. Pharmacol. Ther., 114 (3), 295–306.
20. Kielstein J.T., Veldink H., Martens-Lobenhoffer J. et al. (2011). SDMA is an early marker of change in GFR after living-related kidney donation. Nephrol. Dial. Transplant., 26 (1), 324–328.
21. Liu X., Xu X., Shang R., Chen Y. (2018). Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease. Nitric Oxide, 78, 113–120. doi: 10.1016/j.niox.2018.06.004.
Review
For citations:
Stafeev A.N., Logvinenko N.I., Tereshkov P.P., Melnik A.V., Astrakov S.V. Endogenous inhibitors of nitric oxide synthesis in patients with bronchial asthma associated with arterial hypertension. Journal of Siberian Medical Sciences. 2020;(2):89-97. (In Russ.) https://doi.org/10.31549/2542-1174-2020-2-89-97
Views:
222
Email this article 